Jason Dinges

Jason Dinges has been a member of the Morningside investment team since 2011. He has extensive experience facilitating financings and providing operational and management oversight to early-stage biotechnology companies. Dr. Dinges is a director of several biopharmaceutical or biotechnology companies across a broad spectrum of therapeutic areas including: Adiso Therapeutics, Alentis Therapeutics, CellCentric, ClearB Therapeutics, Geneoscopy, Inotrem, Prilenia Therapeutics, and ZielBio.  From 2006 to 2011, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law. Dr. Dinges received his Ph.D. in genetics from Iowa State University and a J.D., with highest distinction, from the University of Iowa College of Law.